iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Harvoni GT4/5 - EASL/2015-GS9857/GS5816
 
 
  EASL: Ledipasvir/Sofosbuvir for the Treatment of Patients With Chronic Genotype 4 or 5 HCV Infection - (04/29/15)
 
Safety and Efficacy of Treatment with Sofosbuvir + GS-5816 ± Ribavirin for 8 or 12 Weeks in Treatment-Naïve Patients with Genotype 1-6 HCV Infection......
http://www.natap.org/2014/AASLD/AASLD_12.htm
 
Safety and Efficacy of Treatment With Interferon-Free, Ribavirin-Free Combination of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Patients With Genotypes 1-6 HCV Infection......
http://www.natap.org/2014/EASL/EASL_29.htm
 
The ASTRAL Studies: Evaluation of SOF/GS-5816 Single-Tablet Regimen for the Treatment of Genotype 1-6 HCV Infection.......
http://www.natap.org/2015/EASL/EASL_106.htm
 
GS-9857 Pangenotypic Protease Inhibitor + SOF/GS5816 for 6/8 Weeks......
http://www.natap.org/2015/EASL/EASL_138.htm
 
GS-5816, a Once-Daily NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients With Genotype 1-4 HCV Infection in a 3 Day Monotherapy Study......
http://www.natap.org/2013/AASLD/AASLD_13.htm
 
GS-5816, a Second-Generation HCV NS5A Inhibitor With Potent Antiviral Activity, Broad Genotypic Coverage, and a High Resistance Barrier......
http://www.natap.org/2013/EASL/EASL_34.htm

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org